[go: up one dir, main page]

EP4423062A4 - MODIFIED INDOLE COMPOUNDS - Google Patents

MODIFIED INDOLE COMPOUNDS

Info

Publication number
EP4423062A4
EP4423062A4 EP22887993.8A EP22887993A EP4423062A4 EP 4423062 A4 EP4423062 A4 EP 4423062A4 EP 22887993 A EP22887993 A EP 22887993A EP 4423062 A4 EP4423062 A4 EP 4423062A4
Authority
EP
European Patent Office
Prior art keywords
indole compounds
modified indole
modified
compounds
indole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22887993.8A
Other languages
German (de)
French (fr)
Other versions
EP4423062A1 (en
Inventor
Jeanine Yacoub
Elena Bray
Jacqueline Salm
Christopher Witowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Psilera Inc
Original Assignee
Psilera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psilera Inc filed Critical Psilera Inc
Publication of EP4423062A1 publication Critical patent/EP4423062A1/en
Publication of EP4423062A4 publication Critical patent/EP4423062A4/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16Tryptamines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP22887993.8A 2021-10-29 2022-10-24 MODIFIED INDOLE COMPOUNDS Pending EP4423062A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163273710P 2021-10-29 2021-10-29
PCT/US2022/047552 WO2023076150A1 (en) 2021-10-29 2022-10-24 Modified indole compounds

Publications (2)

Publication Number Publication Date
EP4423062A1 EP4423062A1 (en) 2024-09-04
EP4423062A4 true EP4423062A4 (en) 2025-08-27

Family

ID=86159727

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22887993.8A Pending EP4423062A4 (en) 2021-10-29 2022-10-24 MODIFIED INDOLE COMPOUNDS

Country Status (4)

Country Link
US (1) US20250002478A1 (en)
EP (1) EP4423062A4 (en)
JP (1) JP2024540030A (en)
WO (1) WO2023076150A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc New compositions of pharmaceutical substances and preparations
AU2024275806A1 (en) * 2023-05-24 2025-11-20 Psilera Inc. Formulations containing tryptamine derivatives and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079153A1 (en) * 2001-03-28 2002-10-10 Biocatalytics, Inc. Method for producing tryptamine derivatives
WO2020181194A1 (en) * 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
WO2021168082A1 (en) * 2020-02-18 2021-08-26 Gilgamesh Pharmaceuticals, Inc. Specific tryptamines for use in the treatment of mood disorders
WO2021226416A1 (en) * 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
CA2931345A1 (en) * 2013-11-24 2015-05-28 Taipei Medical University Use of indolyl and idolinyl hydroxamates for treating neurodegenerative disorders or cognitive deficits

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079153A1 (en) * 2001-03-28 2002-10-10 Biocatalytics, Inc. Method for producing tryptamine derivatives
WO2020181194A1 (en) * 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
WO2021168082A1 (en) * 2020-02-18 2021-08-26 Gilgamesh Pharmaceuticals, Inc. Specific tryptamines for use in the treatment of mood disorders
WO2021226416A1 (en) * 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MALACA SARA ET AL: "Toxicology and Analysis of Psychoactive Tryptamines", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, no. 23, 12 April 2020 (2020-04-12), XP093014242, DOI: 10.3390/ijms21239279 *
See also references of WO2023076150A1 *

Also Published As

Publication number Publication date
JP2024540030A (en) 2024-10-31
EP4423062A1 (en) 2024-09-04
WO2023076150A1 (en) 2023-05-04
US20250002478A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
DK4165024T3 (en) Cyclobutyldihydroquinolinesulfonamide compounds
EP4253377A4 (en) 5-HETEROARYL-1H-PYRAZOLE-3-AMINE DERIVATIVE
EP4137404A4 (en) MULTICOPTER
DK4320112T3 (en) PYRIDINYL-SUBTITUTED OXOISOINDOLINE COMPOUNDS
EP4186256C0 (en) ADI-HOC NETWORK-SLICE-CROSS-COMMUNICATION
IL310528A (en) Pyrazolopyridinone compounds
PL4301748T3 (en) TRIAZOLYL-METHYL SUBSTITUTED ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES
EP4222352A4 (en) BOLCHER
IL304774A (en) Improved superlipid derivatives
EP3957265A4 (en) MICRODRAPED
IL287177A (en) Chiral indole compounds
EP4423062A4 (en) MODIFIED INDOLE COMPOUNDS
EP4308572C0 (en) THIENOPYRIMIDINONE DERIVATIVES
EP4415710A4 (en) CRYSTALLINE TRYPTAMINE COMPOUNDS
EP4308576C0 (en) THIAZOLOPYRIMIDINONE DERIVATIVES
EP4154884A4 (en) ANTI-SARS-COV-2-DURG
EP4137402A4 (en) MULTICOPTER
DK4396183T3 (en) SUBSTITUTED S-ALANINATE DERIVATIVES
PT4038149T (en) ANTI-FULING COMPOUNDS
EP4377462A4 (en) IMPROVED CRISPR-CAS TECHNOLOGIES
EP4228051A4 (en) LEAD-ACCUMULATOR
EP4221968C0 (en) RADIALPRESSE
EP4320989A4 (en) MR-DC IMPROVEMENTS
IL313590A (en) compounds
IL312389A (en) New benzyltryptamine compounds

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240520

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250728

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 209/16 20060101AFI20250722BHEP

Ipc: A61P 25/30 20060101ALI20250722BHEP

Ipc: A61P 25/28 20060101ALI20250722BHEP